Table 2.
Center | Frankfurt | Frankfurt | Vienna | Vienna | Vienna | Vienna | Vienna | Vienna | Vienna | Vienna |
---|---|---|---|---|---|---|---|---|---|---|
Sex/age (years) | m/11.3 | m/4.7 | m/1.8 | m/11.5 | f/16.5 | f/14.9 | m/16.3 | m/14.6 | f/9.5 | m/16.0 |
Malignancy (risk group) | Rhabdo | CGD | ALL (SR) | ALL (SR) | ALL (HR) | AML | AML | ALL (relapse) | AML (relapse) | AML (relapse) |
Chemo/ HSCT | HSCT | HSCT | Chemo | Chemo | Chemo | HSCT | HSCT | Chemo | Chemo | Chemo |
Time point | Post-engraft | Pre-engraft | Induction | Re-induction | Induction | Pre-engraft | pre-engraft | Induction | Induction | Induction |
Risk factors | S | N | N, S | S | N, S | N | N | N | N | N |
Pathogen | C. krusei | A. fumigatus | C. albicans | A. fum./Rhizopus arrhizus | mold | Fusarium spp. | C. krusei | mold | C. albicans | C. krusei |
Site | Blood (culture) | Lung, brain biopsy (culture) | Blood (culture) | Sinus/maxilla surgery (culture) | Lung biopsy (histology) | Eye/blood/skin (culture skin and blood) | Blood (culture) | Lung biopsy (histology) | Blood (culture) | Blood (culture) |
Prophylaxis | Antimold (LAMB) | Antimold (Vori) | No | No | Antimold (LAMB/Vori∗) | Antimold (Posa) | No | Antimold (Vori) | Antimold (Vori) | Antimold (Posa) |
Outcome IFD | CR | Death | CR | PR | CR | CR | Death | CR | CR | CR |
Outcome | Death unrelated to IFD | Death due to IFD | Alive | Alive | Alive | Alive | Death due to IFD | Death unrelated to IFD | Death unrelated to IFD | Death unrelated to IFD |
F, female; m, male; AML, acute myeloid leukemia; ALL, acute lymphoblastic leukemia; ALL-SR, ALL-standard-risk group; ALL-HR, ALL-high-risk group; rhabdo rhabdomyosarcoma; CGD, chronic granulomatous disease; chemo chemotherapy; HSCT, hematopoietic stem cell transplantation; engraft engraftment; N, prolonged neutropenia (<500 neutrophils/mm3 >10 days); S use of corticosteroids at a mean minimum dose of 0.3 mg/kg/day prednisone equivalent for more than 3 weeks; LAMB, liposomal amphotericin B; Vori voriconazole; Posa posaconazole; CR, complete remission; PR, partial remission; IFD, invasive fungal disease.